When Rochelle Eroh, of Hamburg, PA, was diagnosed with hormone receptor negative and HER2 neu negative (also known as triple negative) breast cancer, she quickly learned this was a more aggressive type of breast cancer. Given her young age and the size of her tumor, Lehigh Valley Health Network medical oncologist, Nicholas Lamparella, DO, provided Rochelle with information regarding a clinical trial for a neo-adjuvant chemotherapy regimen. She received the standard of care Paclitaxel, plus or minus two additional drugs, Carboplatin and Veliparib. In this video, Rochelle, breast cancer surgeon, Lori Alfonse, DO, and Rochelle’s clinical trial nurse, Morgan Horton, describe Rochelle’s experience and the additional level of care provided as part of the clinical trial. Lehigh Valley Health Network is part of the Memorial Sloan Kettering Cancer Alliance, an initiative to improve the quality of care and outcomes for patients with cancer in community health settings. Innovations at MSK, a world leader in cancer research, brings the latest treatments to community providers – and their patients – at an accelerated pace. For more information, call 610-402-CARE or go to LVHN.org/cancer.